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Abstract
Introduction: Plasmacytoid dendritic cells (pDCs) play not only a central role in the antiviral immune response in 
innate host defense, but also a pathogenic role in the development of the autoimmune process by their ability to 
produce robust amounts of type I interferons (IFNs), through sensing nucleic acids by toll-like receptor (TLR) 7 and 9. 
Thus, control of dysregulated pDC activation and type I IFN production provide an alternative treatment strategy for 
autoimmune diseases in which type I IFNs are elevated, such as systemic lupus erythematosus (SLE). Here we focused 
on IκB kinase inhibitor BAY 11-7082 (BAY11) and investigated its immunomodulatory effects in targeting the IFN 
response on pDCs.
Methods: We isolated human blood pDCs by flow cytometry and examined the function of BAY11 on pDCs in 
response to TLR ligands, with regards to pDC activation, such as IFN-α production and nuclear translocation of 
interferon regulatory factor 7 (IRF7) in vitro. Additionally, we cultured healthy peripheral blood mononuclear cells 
(PBMCs) with serum from SLE patients in the presence or absence of BAY11, and then examined the inhibitory function 
of BAY11 on SLE serum-induced IFN-α production. We also examined its inhibitory effect in vivo using mice pretreated 
with BAY11 intraperitonealy, followed by intravenous injection of TLR7 ligand poly U.
Results: Here we identified that BAY11 has the ability to inhibit nuclear translocation of IRF7 and IFN-α production in 
human pDCs. BAY11, although showing the ability to also interfere with tumor necrosis factor (TNF)-α production, 
more strongly inhibited IFN-α production than TNF-α production by pDCs, in response to TLR ligands. We also found 
that BAY11 inhibited both in vitro IFN-α production by human PBMCs induced by the SLE serum and the in vivo serum 
IFN-α level induced by injecting mice with poly U.
Conclusions: These findings suggest that BAY11 has the therapeutic potential to attenuate the IFN environment by 
regulating pDC function and provide a novel foundation for the development of an effective immunotherapeutic 
strategy against autoimmune disorders such as SLE.
Introduction
Although only a small fraction of cells, plasmacytoid den-
dritic cells (pDCs) represent a major source of type I
interferons (IFNs) in peripheral blood mononuclear cells
(PBMCs) and lymphoid tissues in both humans and mice
[1,2], they play a central role in the innate antiviral
immune response by their ability to rapidly produce
robust amounts of type I IFNs upon viral infection. This
function is through their selective expression of toll-like
receptor (TLR)7 and TLR9, which respectively sense viral
RNA and DNA within the early endosomes [3]. Recent
studies have uncovered the molecular basis underlying
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the specialized ability of pDCs to mount their rapid and
massive IFN response. The type I IFN production
requires IFN regulatory factor (IRF)7 to be phosphory-
lated and translocated into the nucleus through rapid
interaction with MyD88 and IRF7 [4]. pDCs are found to
constitutively express high levels of IRF7 and the endoge-
nous IRF7 facilitates a rapid type I IFN response that is
independent of type I IFN receptor-mediated feedback
signaling [3,5,6]. IRF7 is activated by forming cytoplasmic
multiple signal-transducing complex with tumor necrosis
factor (TNF) receptor-associated factor (TRAF)6 and
interleukin (IL)-1 receptor-associated kinase (IRAK)4
through ubiquitylation and phosphorylation, and in turn
interacts with TRAF3, IRAK1, osteopontin, and phos-
phatidylinositol-3 kinase (PI3K) [7-10]. A recent observa-
tion that pDCs barely express the translational inhibitors
4E-BP1 and 4E-BP2, which play a role in repression of
Irf7 mRNA translation [11], could plausibly explain the
constitutive expression of high levels of IRF-7 in pDCs.
Thus, these unique molecular mechanisms endow pDCs
with the specialized innate ability of IFN response upon
viral infection.
Alternatively, a series of recent analyses have revealed
that pDCs also play a pathogenic role in autoimmune dis-
eases such as systemic lupus erythematosus (SLE) and
psoriasis by their dysregulated production of type I IFNs
through engagement of endosomal TLR9 by self-DNA
with autoantibody [12-15]. Secretion of type I IFNs is
believed to be a central molecular event that initiates and
promotes the autoimmune process [12,14]. Type I IFNs
induce the differentiation of myeloid DCs from mono-
cytes, which in turn promote the differentiation of auto-
reactive CD4+ T cells, CD8+ T cells, and B cells. These
autoreactive effectors injure tissues, resulting in the pro-
duction of nucleic acid fragment and auto anti-nuclear
antibody. This in turn induces the production of immune
complexes containing self-DNA or RNA. The immune
complexes further activate pDCs through TLRs in a sus-
tained fashion, amplifying the vicious spiral based on the
type I IFNs. Accordingly, pDCs and type I IFNs represent
specific cellular and molecular targets in therapeutic
strategies against these autoimmune diseases.
BAY11-7082 (BAY11), (E)-3-(4-methylphenylsulfonyl)-
2-propenenitrile, was initially identified as a compound
that inhibits the NF-κB pathway and leads to the
decreased expression of endothelial cell adhesion mole-
cules [16] and paw swelling in a rat adjuvant arthritis
model [17]. Further studies searching for alternative ther-
apeutic strategies against malignancies have shown that
this compound is a potent inducer of apoptosis in a num-
ber of malignant cells such as in colorectal cancer [18]
and breast cancer [19], as well as leukemia, myeloma
cells, and lymphoma cells [20-24].
BAY11 is found to inhibit the upstream signaling pro-
cess of NF-κB activation; namely it functions as an inhibi-
tor for the action of the IκB kinase (IKK) complex, which
consists of the catalytic kinase subunits IKKα and IKKβ
[18,25].
Given a recent study showing that the activation of
IRF7 depends on an IKK subfamily IKKα at the down-
stream of the TLR7/9-MyD88 pathway in pDCs [26],
IKKα would be a potential molecular target for the treat-
ment of type I IFN-related autoimmune diseases. As
might be inferred from the function of BAY11 as inhibi-
tor of IKK activity, we hypothesized that this compound
could have the potential to repress the IFN response in
pDCs through preventing IRF7 nuclear translocation,
which may lead to an alternative treatment strategy for
the autoimmune diseases.
We here show a novel function of BAY11, which inhib-
ited IFN-α production by human pDCs as well as mouse
pDCs upon TLR ligand activation by inhibiting the
nuclear translocation of IRF7. We also showed its inhibi-
tory effect in vivo by the observation that treatment with
BAY11 attenuates the elevated level of serum type I IFNs
in mice that were injected with TLR ligands. Our current
results serve as the foundation for the development of an
effective immunotherapeutic strategy to repress the auto-
immune disorders induced by type I IFNs.
Materials and methods
Media and reagents
RPMI-1640 supplemented with 2 mM L-glutamine, 100
U/ml penicillin, 100 ng/ml streptomycin and heat-inacti-
vated 10% fetal bovine serum (Biosource International,
Camarillo, CA, USA) was used for cell cultures through-
out the experiments. For human cell stimulation, we used
5 μM CpG-ODNs 2216 (Invivogen, San Diego, CA, USA),
100 μM Loxoribine (Invivogen), 1 μg/ml R848 (Invivo-
gen), and 10 μg/ml Poly(I:C) (Invivogen). For mouse cell
stimulation, we used 3 μg/ml polyuridine RNA (Poly U)
(Sigma-Aldrich, St. Louis, MO, USA) in complex with
lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA)
according to the manufactuer's protocol. BAY11-7082
(Alexis, San Diego, CA, USA) was dissolved in DMSO.
DMSO was diluted in parallel to serve as a vehicle con-
trol.
Cell isolation and culture
Human peripheral blood DC subsets (myeloid DCs and
pDCs) were isolated from PBMCs from healthy adult
donors, as described previously [3,27]. Written informed
consent was obtained from all healthy adult donors.
CD11c+/BDCA4-/lineage-/CD4+ cells (as myeloid DCs)
and CD11c-/BDCA4+/lineage-/CD4+ cells (as pDCs) were
s o r t e d  b y  F A C S  A r i a ® (BD Biosciences, San Jose, CA,
USA) to reach greater than 99% purity according toMiyamoto et al. Arthritis Research & Therapy 2010, 12:R87
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restaining with anti-BDCA1 or anti-BDCA2. Mouse
splenic pDCs (CD11c+B220+CD11b-) were isolated by
FACS Aria® as described previously [28]. The DC subsets
or PBMCs were preincubated for 15 minutes or 1 h with
BAY11 (10-9 to 10-5 M) or vehicle. Poly(I:C), CpG, R848,
Loxoribine, or poly U+lipofectamine was then added into
this culture in flat-bottomed 96-well plates at 5 × 104 cells
(2 × 105 cells for PBMCs) in the final 200 ml of medium
per well for 24 h.
Lupus PBMCs and serum, and preparation of necrotic cell 
supernatants
PBMCs and sera were obtained from three active SLE
patients with low complements prior to steroid therapy
and who satisfied five criteria in the American College of
Rheumatology (ACR) classification for SLE [29]. Written
informed consent was obtained for all SLE patients. All
patients had anti-double-stranded DNA antibody.
Necrotic cell supernatants were prepared from KM-H2
(human Hodgkin's Reed-Sternberg line), which was
g r o w n  i n  R P M I  w i t h  2 0 %  o f  f e t a l  b o v i n e  s e r u m ,  a n d
necrosis was induced by the freeze-thaw method. Briefly,
freeze-thawing was performed in four cycles of both 10
minutes freezing at -80°C and thawing at 37°C. Lupus-
PBMCs were stimulated with CpG-2216 with autologous
20% serum in flat-bottomed 48-well plates at 106 cells in
500 μl of medium per well. Alternatively, healthy PBMCs
were stimulated with 20% lupus serum with or without
20% necrotic cell supernatant in flat-bottomed 96-well
plates at 2 × 105 cells in 200 μl of medium per well. This
study was approved by the Institutional Review Board of
Kansai Medical University and the research was in com-
pliance with the Helsinki declaration.
In vivo assessment of cytokine productions
C57BL/6 mice (purchased from CLEA Japan, Meguro,
Tokyo, Japan) were pretreated with BAY11 (10 mg/kg or 5
mg/kg bodyweight) or vehicle as control for 1 h intraperi-
tonealy, followed by intravenous injection of poly U (50
μg/head) + in vivo-jetPEI (Polyplus-transfection, lllkirch,
France) (according to the manufacturer's protocol). We
analyzed the serum IFN-α levels at several time points
(one, three, and six hours). All mice were maintained
until used in the animal facilities under specific patho-
gen-free conditions. All animal researches were reviewed
and approved by the Animal Ethical Committee of
RIKEN Research Center.
Analyses of cells
Human pDCs were stained with FITC-labeled CD86 (BD
Biosciences) and then analyzed by FACScalibur® (BD Bio-
sciences). The production of cytokines in the culture
supernatants after 24 hours was determined by ELISA
(ELISA kits for human and mouse TNF-a and IL-12 p40
were purchased from R&D systems, (Minneapolis, MN,
USA). ELISA Kits for human and mouse IFN-a were pur-
chased from PBL Biomedical Laboratories (Piscataway,
NJ, USA).
Intracellular cytokine staining in human pDCs was per-
formed after eight hours of culture with different stimuli.
Brefeldin A (10 μg/ml; Sigma-Aldrich, St. Louis, MO,
USA) was added during the last two hours. After stimula-
tion, cells were fixed and permeabilized using the FIX and
PERM kit (Invitrogen, Carlsbad, CA, USA) and then
stained with FITC-labeled anti-IFN-α2 mAb (Chro-
maprobe, Maryland Heights, MO, USA) phycoerythrin
(PE)-labeled anti-TNF-α mAb (PBL Biomedical Labora-
tories), and allophycocyanin (APC)-labeled anti-BDCA4
mAb (Miltenyi Biotec, Bergisch Gladbach, Germany).
Dead cells were excluded on the basis of side- and for-
ward-scatter characteristics. In the viability assay, cells
were washed with phosphate-buffered saline(PBS) con-
taining 2 mM EDTA, and viable cells were counted in
triplicate with trypan-blue exclusion of the dead cells.
Viable cells were also evaluated using Propidium Iodide
staining (Calbiochem, San Diego, CA, USA).
Detection of p-NF-κB p65 expression
Human pDCs were stimulated with CpG-2216 or loxorib-
ine at 90 minutes, and the cells were immediately fixed
and stained with Alexa Fluor-488 anti-p-NF-κB p65
(pS529; BD Biosciences) according to BD Phosflow's
instructions, and then analyzed by FACS calibur.
Confocal microscopy
C e l l s  w e r e  s e e d e d  o n  g l a s s  s l i d e s  b y  c y t o s p i n  a n d
mounted, and were then fixed with 2% paraformaldehyde
and permeabilized with 100% ice-cold methanol for 10
minutes at -20°C. Samples were labeled with rabbit poly-
clonal anti-human IRF-7 (H-246, Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA) and 4',6'-diamidino-2-
phenylindole (DAPI). Anti-rabbit IgG-Cy5 (Invitrogen,
Carlsbad, CA, USA) was used as secondary antibody.
Images were acquired using a confocal microscope (LSM
510 META; Carl Zeiss, Inc. (Jena, Germany)).
Results
BAY11 inhibits IFN-α production from human PBMCs
In the first set of experiments, we assessed the immuno-
modulatory properties of BAY11 on human PBMCs.
Because BAY11 was shown to have a cytotoxic activity at
high concentrations [30], we analyzed the survival of
PBMCs in the presence of different doses of BAY11 by
propidium iodide (PI) staining (Figure 1A). Although a
very high concentration (10-5 M) of BAY11 induced cell
death as shown by the more than 50% of PI expression in
PBMCs, 10-9 M to 10-6 M of BAY11 did not increase PI-
positive cells. We next measured the TLR ligand-inducedMiyamoto et al. Arthritis Research & Therapy 2010, 12:R87
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cytokine production by PBMCs in the presence of 10-9 M
to 10-6 M of BAY11. We found that IFN-α production by
PBMCs in response to IFN-inducing TLR ligands (TLR9
ligand CpG 2216, TLR7/8 ligand R848, or TLR7 ligand
loxoribine) were markedly inhibited in a dose-dependent
manner (Figure 1B). By contrast, TNF-α production by
PBMCs in response to these TLR ligands was only mod-
estly inhibited by the 10-6 M of BAY11. Similarly, IL-12
production induced by R848 was prevented by the 10-6 M
of BAY11.
BAY11 directly inhibits IFN-α production from human pDCs
Next, to investigate whether BAY11 functions directly on
pDCs, as the major source of type I IFNs, to inhibit the
IFN response, we used purified pDCs in the cultures with
different doses of BAY11. Because pDCs are very fragile
[27], we used a titration assay of BAY11 (10-9 M to 10-5 M)
to test the viability of pDCs and determine the concentra-
tion range of BAY11 that does not induce cell death.
Analysis of trypan-blue exclusion of the dead cells (Figure
2A) and PI staining (Figure 2B) showed that over 10-6 M
of BAY11 killed pDCs even in response to TLR-stimuli
but that there were no significant differences in the rate
of viable cells between the condition without BAY11 and
with up to 3 × 10-7 M of BAY11. Therefore, we thereafter
used 10-9 M to 3 × 10-7 M of BAY11 for the following
assays.
We further investigated the effect of BAY11 on the pDC
maturation. Up to 3 × 10-7 M of BAY11 did not influence
the CD86 expression on pDCs in response to CpG or lox-
oribine (Figure 2C).
We measured TLR-mediated cytokine production by
purified pDCs in the presence or absence of BAY11. We
found that IFN-α production by pDCs in response to
Figure 1 BAY11 inhibits IFN-α production from human PBMCs. (A) Human PBMCs were incubated for 24 h with BAY11 (10-9 to 10-5 M) or vehicle. 
Viable cells were analyzed by propidium iodide (PI) staining. Similar results were observed in five independent donors and the results of a represen-
tative experiment are shown. (B) Human PBMCs were preincubated for 15 minutes with BAY11 or vehicle, followed by addition of 5 μM CpG 2216, 1 
μg/ml R848 and 100 μM loxoribine (loxo). After 24 h, the concentrations of IFN-α, TNF-α or IL-12 p40 in the culture supernatants were measured by 
ELISA. Data are shown as mean ± SEM of four independent donors. Statistical significance was determined using Mann-Whitney test (*P < 0.05 **P < 
0.01).Miyamoto et al. Arthritis Research & Therapy 2010, 12:R87
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CpG 2216 and loxoribine were severely impaired by
BAY11 in a dose-dependent manner between 10-9 M to 3
× 10-7 M (Figure 3A). However, the inhibitory response of
TNF-α production was more modest than that of IFN-α
production. Namely, the TNF-α production was not pre-
vented by a BAY11 concentration of between 10-9 and 10-
8 M, which significantly inhibited the IFN-α production
(Figure 3A). Further analysis with intracellular cytokine
staining also showed severe defects in both IFN-α and
TNF-α expression in CpG-stimulated pDCs after expo-
sure to 3 × 10-7 M of BAY11, but only a decrease in IFN-
α- expressing cells after exposure to 10-8 M (Figure 3B).
These findings suggest that the effective dose of BAY11
on pDCs can be divided into three concentration ranges;
low: 10-9 M to 10-8 M of BAY11, which selectively inter-
fered with IFN-α production; medium: 10-8 M to 3 × 10-7
M of BAY11, which exhibited an inhibitory effect on the
production of both IFN-α and TNF-α; and high: over 10-6
M of BAY11, which had a cytotoxic impact.
BAY11 is incapable of interfering with poly IC-induced IFN-
α production from myeloid DCs
In PBMCs, IFN-α production through TLR signaling
mainly depends on pDCs. However, PBMCs contain
monocytes and myeloid DCs, which can produce type I
IFNs upon RNA recognition, though IFN-α production is
much less than with pDCs [31]. Poly IC stimulated myel-
oid DCs to produce IL-12 and IFN-α through triggering
endosomal TLR3 and cytosolic MDA5 [32]. We therefore
examined whether BAY11 inhibits the production of
these cytokines by myeloid DCs. Although TNF-α and
IL-12 production were impaired by 10-7 M of BAY11,
IFN-α production was not significantly inhibited by doses
of up to 3 × 10-7 M of BAY11 (Figure 4). Up to 3 × 10-7 M
Figure 2 Effects of BAY11 on pDC survival and maturation. 10-9 M to 3 × 10-7 M of BAY11 does not affect viability or maturation of pDCs. Human 
pDCs were preincubated for 15 minutes with different concentrations of BAY11 (10-9, 3 × 10-9, 10-8, 3 × 10-8, 10-7, 3 × 10-7, 10-6, 3 × 10-6 ,10-5 M) or ve-
hicle. CpG 2216 or loxo were then added to the pDC cultures. After 24 h, viable cells were measured by a trypan-blue exclusion test (A) and PI staining 
(B), and CD86 expression on pDCs was analyzed by flow cytometry (C). Percentages of PI-positive cells are indicated in B. Numbers in the histograms 
(C) indicate the mean fluorescence intensity (MFI), which is calculated by the subtraction of MFI with the isotype control from that with CD86 mAb. 
Similar results were observed in three independent donors and the results of a representative experiment are shown.Miyamoto et al. Arthritis Research & Therapy 2010, 12:R87
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of BAY11 did not induce a PI-positive cell rate of myeloid
DCs (data not shown).
BAY11 inhibits nuclear translocation of IRF7 in pDCs
Because the key molecular step in the type I IFN produc-
tion by pDCs in response to ligand for TLR7 or TLR9 has
been elucidated to be nuclear translocation of the consti-
tutive expression of IRF7 [3,33], we assessed whether
BAY11 inhibits this process in pDCs. Analysis with
immunofluorescence microscopy revealed that IRF7 was
constitutively expressed and localized in the cytoplasmic
area of unstimulated pDCs (Figure 5A). After three hours
stimulation of CpG, IRF7 was detected in the nucleus, as
Figure 3 BAY11 inhibits IFN-α production from human pDCs. Human pDCs were preincubated for 15 minutes with different concentrations of 
BAY11 (10-9, 3 × 10-9, 10-8, 3 × 10-8, 10-7, 3 × 10-7) or vehicle. CpG 2216 or loxo were then added to the pDC cultures. (A) After 24 hours, the concentra-
tions of IFN-α and TNF-α in the culture supernatants were measured by ELISA. Data are shown as mean ± SEM of four independent donors. Statistical 
significance was determined using Mann-Whitney test (*P < 0.05, **P < 0.01). (B) After eight hours of stimulation with CpG 2216, intracellular cytokine 
(IFN-α and TNF-α) expression and surface BDCA4 expression by pDCs were analyzed by flow cytometry. Percentages of the cytokine-producing pDCs 
are indicated in each dot-blot profile. Similar results were observed in three independent donors and the results of a representative experiment are 
shown.
Figure 4 BAY11 does not affect poly IC-induced IFN-α production. Human myeloid DCs were pretreated for 15 minutes with different concen-
trations of BAY11 (10-9, 3 × 10-9, 10-8, 3 × 10-8, 10-7, 3 × 10-7) or vehicle, followed by addition of 10 μg/ml poly IC. After 24 hours, the concentrations of 
IFN-α, TNF-α and IL-12 in the culture supernatants were measured by ELISA. Data are shown as mean ± SEM of four independent donors. Statistical 
significance was determined using Mann-Whitney test (*P < 0.05, **P < 0.01).Miyamoto et al. Arthritis Research & Therapy 2010, 12:R87
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Figure 5 BAY11 inhibits nuclear translocation of IRF7 and NF-κB phosphorylation in pDCs upon TLR-mediated activation. Human pDCs were 
pretreated for 15 minutes with BAY11 (10-9 to 10-7 M) or vehicle, followed by addition of CpG 2216 and cultured for three hours. (A, B) Freshly isolated 
or activated pDCs were visualized by immunofluorescence with IRF7 antibody (Cy5, red) and nuclei staining with DAPI (blue). Similar results were ob-
served in four independent donors and the representative cells are shown in (A). Cells without nuclear IRF7 expression were counted on the slide from 
four independent donors (B). Cells were regarded as negative when the expression level of IRF7 in the cytoplasm was higher and distinguishable from 
that in the nucleus, shown by DAPI staining. Ratio of nuclear IRF7-negative cells was analyzed by 50 cells in each donor. Statistical significance was 
determined using Mann-Whitney test (**P < 0.01). (C) Staining with anti-p-NF-κB p65 mAb (shaded) and isotype-matched control (solid line) for freshly 
isolated pDCs or activated pDCs are shown. Similar results were observed in three independent donors and the results of a representative experiment 
are shown.Miyamoto et al. Arthritis Research & Therapy 2010, 12:R87
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shown by colocalization with DAPI nuclear staining,
indicating the nuclear translocation of IRF7. This colocal-
ization of IRF7 and DAPI staining was prevented by the
presence of 10-8 M and 10-7 M of BAY11 (Figure 5A).
Thus, BAY11 helped retain IRF7 in the cytoplasm, indi-
cating an inhibitory effect of IRF7 nuclear translocation
in pDCs. To show this finding quantitatively, we counted
the cell numbers with or without nuclear IRF7 expression
in pDCs on the slide, as described [10]. The frequency of
cells without IRF7 nuclear translocation was significantly
augmented by BAY11 in response to CpG (Figure 5B).
Thus, our result identifies that BAY11 acts as an inhibitor
of IRF7 nuclear translocation and indicates that the inhi-
bition of type I IFN production by BAY11 is due to its
inhibitory function on the nuclear translocation of IRF7.
Unlike type I IFN production, inflammatory cytokine
and chemokine production have been shown to be mostly
through NF-κB activation [34]. Because BAY11 was ini-
tially identified as a potent inhibitor of NF-κB pathway,
we confirmed its function in regard to NF-κB activation
in pDCs. Analysis with flow cytometry (Figure 5C)
showed that although 10-9 M and 10-8 M of BAY11 only
slightly decreased the intensity of TLR-induced NF-κB
phosphorylation, 10-7 M of BAY11 strongly interfered
with the NF-κB phosphorylation in accord with TNF-α
production (Figure 3A).
BAY11 inhibits both IFN-α production by lupus-PBMCs and 
lupus serum-induced IFN-α production
Formation of immune complexes in serum consisting of
autoantibodies and self-DNA in SLE continuously trig-
gers the type I IFN production by blood pDCs, causing
the development of the autoimmune process. Thus, the
pDCs and serum represent the pathogenic cellular and
humoral factors in SLE. In some previous in vitro experi-
ments, stimulation of PBMCs with serum obtained from
a patient with SLE induced IFN-α production, and serum
containing DNA from necrotic cell supernatant enhanced
the IFN-α production [35,36]. Based on these findings,
we designed additional experiments using PBMCs and
serum from patients with SLE, as described [36,37], to
assess whether BAY11 functions as an inhibitor of type I
IFN production under the pathophysiological condition
of SLE. Initially, PBMCs from SLE patients were stimu-
lated with CpG in the medium containing 20% auto-
serum. Because blood pDCs in SLE are continuously trig-
gered by serum immune complexes, the numbers of cir-
culating pDCs are decreased and their function is
defective [38,39]. Despite the low IFN response to CpG in
lupus-PBMCs, we found that BAY11 had the ability to
inhibit the IFN-α production even in the pathogenic
PBMCs in a dose-dependent way (Figure 6A). Also in this
experimental setting, 10-5 M of BAY11 slightly induced
PI-positive cells, but 10-9 M to 10-6 M of BAY11 did not
increase PI expression in the PBMCs (data not shown).
Next, we cultured healthy PBMCs with medium contain-
ing 20% of serum from SLE patients with or without 20%
necrotic cell supernatants in the presence or absence of
BAY11, and then measured the concentration of IFN-α.
We preliminarily tested sera from three patients with
active SLE having anti-double-stranded DNA antibody,
and selected the best serum for inducing IFN-α by
healthy PBMCs (data not shown). BAY11 inhibited the
SLE serum-induced IFN-α production by PBMCs (Figure
6B). We next confirmed the observation that necrotic cell
supernatants enhanced the SLE serum-induced IFN-α
production by PBMCs (Figure 6B). BAY11 exerted the
inhibitory function on the necrotic cell supernatant-
enhanced IFN-α production from PBMCs in a dose-
dependent way. We observed a similar inhibitory effect of
BAY11 in this experimental setting using serum from two
other SLE patients (data not shown). These data suggest
that BAY11 has an inhibitory potential in relation to the
pathogenic conditioned IFN-α production under in vitro
experiments.
BAY11 inhibits inducible IFN-α production in vivo
Finally, to weigh up the possibility of inhibiting type I IFN
production through BAY11 therapy in SLE, we evaluated
the in vivo effect of BAY11 on the IFN response in mice.
Preliminarily, we tested whether BAY11 functions in rela-
tion to mouse pDCs in the same way as in humans in
vitro. We found that the production of IFN-α from sorted
splenic pDCs of C57BL/6 mice in response to poly U in
complex with lipofectamine was significantly decreased
by the addition of BAY11 (Figure 7A). There was no dif-
ference in the rate of viable cells up to 10-7 M of BAY11
(Figure 7B). Based on these in vitro findings, we next ana-
lyzed the serum IFN-α level at several time points after
the injection of poly U in C57BL/6 mice pretreated with
or without BAY11 (Figure 7C). Injecting mice with poly U
rapidly increased the serum IFN-α level from one hour
and continued to six hours after poly U injection. Pre-
treatment with both 5 mg/kg and 10 mg/kg of BAY11
prevented any serum IFN-α increases at all time points
(one, three, and six hours). These data suggest that treat-
ment with BAY11 could inhibit the in vivo IFN response
by limiting pDC function when stimulated by TLR ligand.
Discussion
The present study shows that IKK-neutralizing com-
pound BAY11 affects IFN-α production mainly through
its action on pDCs. IFN-α production is differentially reg-
ulated from other inflammatory cytokine production by
the specific intracellular signaling under TLR activation
[40]. A key molecular switch responsible for IFN-α syn-
thesis in pDCs is the nuclear translocation of IRF7 [5].
We here found that BAY11 inhibits the nuclear transloca-Miyamoto et al. Arthritis Research & Therapy 2010, 12:R87
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Figure 6 BAY11 inhibits in vitro pathogenic conditioned IFN-α production. (A) PBMCs from three patients with SLE were isolated and 1 × 106 
cells were preincubated for 15 minutes with BAY11 (10-9 to 10-5 M) or vehicle in the presence of the autologous serum (at a final concentration of 20% 
vol/vol) in 500 μl of medium per well with 5 μM CpG 2216 for 24 hours. Data are shown as mean ± SEM of three independent experiments. Statistical 
significance was determined using paired Student's t test (*P < 0.05 **P < 0.01). (B) Human healthy PBMCs were preincubated for 15 minutes with 
BAY11 (10-9 to 10-7 M) or vehicle in the serum-free RPMI, and the serum of a SLE patient (at a final concentration of 20% vol/vol) with or without necrotic 
cell supernatant (at a final concentration of 20% vol/vol) was then added. After 24 hours, the concentrations of IFN-α in the culture supernatants were 
measured by ELISA. Data are shown as mean ± SEM of four independent donors. Statistical significance was determined using Mann-Whitney test (*P 
< 0.05 **P < 0.01).Miyamoto et al. Arthritis Research & Therapy 2010, 12:R87
http://arthritis-research.com/content/12/3/R87
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tion of IRF7 in pDCs and their IFN-α production.
Although there are a number of reports showing the
potential use of BAY11 in the treatment of malignancies
through its inhibitory activity of NF-κB, the evidence
linking it to autoimmune diseases is scant and there is no
direct evidence so far that BAY11 prevents the activity of
type I IFN-related diseases such as SLE. pDC activation
in the blood by self-nucleic acids is regarded as a patho-
genic trigger of the autoimmune process, and a dysregu-
lated type I IFN elevation in serum by the continuous
pDCs activation amplifies the pathogenic spiral in SLE
[12-14]. On the basis of our current results showing that
BAY11 inhibited the IFN-α production in PBMCs from
SLE patients as well as from healthy donors, treatment
with BAY11 may have the potential to attenuate the IFN
environment and in turn to break off the pathogenic spi-
ral in autoimmune diseases by limiting the disordered
pDC function. Also, the experiments in injecting mice
with poly U are suggestive of the agent's potential in
inhibiting the inducible IFN response in vivo, though the
serum IFN elevation is not pathophysiologically but arti-
ficially induced in our experimental setting.
Under normal physiological conditions, host-derived
self-nucleic acids usually have little chance of encounter-
ing endosomal TLR7 and TLR9 because of their instabil-
ity in relation to nucleases and by their location separate
from endosomes. However, a breakdown in the innate
tolerance to self-nucleic acids occurs when tissue injury
or necrosis release some endogenous molecules, includ-
ing antimicrobial peptide (LL37) and nuclear protein
Figure 7 BAY11 inhibits mouse pDC-derived IFN-α production and serum IFN-α elevation in vivo. (A, B) Sorted mouse splenic pDCs were pre-
incubated for one hour with different concentrations of BAY11 (10-9 to 10-6 M) or vehicle. The pDCs were then cultured for a further 24 hours with poly 
U in complex with lipofectamine. (A) The concentrations of IFN-α in the culture supernatants were measured by ELISA. Data are shown as mean ± SEM 
of five independent experiments. (B) Viable cells were measured by a trypan-blue exclusion test. Similar results were observed in three independent 
experiments and the results of a representative experiment are shown. (C) C57BL/6 mice pretreated intraperitonealy with BAY11 (10 mg/kg or 5 mg/
kg bodyweight) or vehicle for one hour, followed by intravenous injection of 50 μg/head poly U. Serum IFN-α was measured at several time points 
(one, three, and six hours). Bars indicate means of five independent experiments (except at six hours: n = 4). Statistical significance was determined 
using Mann-Whitney test (*P < 0.05 **P < 0.01).Miyamoto et al. Arthritis Research & Therapy 2010, 12:R87
http://arthritis-research.com/content/12/3/R87
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(high-mobility group box 1 protein; HMGB1), which help
to promote stabilization and delivery of immune com-
plexes into early endosomes [9,41,42]. Even in the current
experiments using SLE sera and necrotic cell supernatant
that perhaps comprise these molecules, BAY11 functions
as an inhibitor of the pathogenic IFN-α response. Thus,
our findings provide an opportunity for the development
of therapeutic strategies that directly inhibit the patho-
genic cellular and molecular components leading to SLE.
Also TNF-α production in pDCs was repressed by
BAY11 at the high concentration, and accordingly the
therapeutic window of BAY11 for selective interference
with IFN-α was narrow. Since endogenous TNF-α limits
the IFN-α production in pDCs [43], there is a possibility
that the repression of TNF-α results in abating the inhibi-
tory function of BAY11 against IFN-α production at high
concentration. Thus, the most efficient and practical bio-
logical concentration may need to be decided from fur-
ther studies.
At the downstream of TLR7/9-MyD88, the signaling
pathway bifurcates into NF-κB- and IRF-7- activation
pathways, which are responsible for the induction of
proinflammatory cytokines and type I IFNs, respectively
[2,5]. Whereas IRF7 phosphorylation and nuclear trans-
location depend on IKKα, NF-κB activation needs IKKβ.
IKKβ homodimer can compensate the function of het-
erodimer of IKKα and IKKβ in activating NF-κB in the
absence of IKKα [40]. Given the function of BAY11 as an
inhibitor of IKK activity [18,25], a more plausible expla-
nation for its inhibitory activities in regards to both IFN-
α and TNF-α in pDCs is that BAY11 targets IKKα in the
inhibition of IFN-α and IKKβ in the inhibition of TNF-α
at the downstream of TLR7/9-MyD88.
The other two IKK-related kinases, TANK-binding
kinase 1 (TBK1) and IKKτ (also called as IKKε), are also
reported to be involved in the phosphorylation of IRF-7
as well as IRF3 [44]. However, CpG-induced IFN-α secre-
tion is not impaired in mice deficient in TBK1 or IKKτ
[7], indicating that these two IKKs are dispensable for
TLR-mediated induction of IFN-α in pDCs. Similar to
IKKα deficiency, IRAK1 deficiency leads to the defective
transcriptional activation of IRF7 and defective produc-
tion of IFN-α gene in pDCs [8], indicating a critical
involvement of IRAK1 in the induction of type I IFNs in
TLR7 and TLR9 signaling pathways. Although it is
unclear at present how IKKα links to IRAK1, either
kinase appears to be the gateway for activation of IRF7 to
induce IFN-α production in pDCs and both could be
potential targets for the treatment of autoimmune disor-
ders. Further studies will be required to determine what
the specific target of BAY11 is, whether BAY11 inhibits
IRAK1 activationor the precise mechanism by which
BAY11 inhibits the signaling pathway of TLR-mediated
IFN-α production in pDCs.
In contrast to RNA-sensing receptor TLR7 in pDCs,
another RNA-sensing cytosolic RIG-I-like receptor sen-
sors in myeloid DCs through recognition of dsRNA such
as poly IC can also induce IFN-α/β in an IPS-1-depen-
dent manner [45]. However, BAY11 was incapable of
inhibiting the poly IC-induced IFN-α production by
myeloid DCs. This finding can be explained by the evi-
dence that, at the downstream of RIG/MDA5-IPS-1, both
IKKα and IKKβ are dispensable for the type I IFN pro-
duction [9,32]. However, BAY11 could suppress the poly
IC-induced IL-12 and TNF-α secretion by the myeloid
DCs. This could also be explained by the evidence show-
ing that TLR3-mediated production of proinflammatory
cytokines is dependent on IKKβ during the signaling pro-
cess of the TRIF-NF-κB pathway [40].
Conclusions
Collectively, our data demonstrated an antagonistic prop-
erty of BAY11 to the in vitro and in vivo IFN response and
imply a possibility for new therapeutic approaches by
interference with the pathogenic components of autoim-
mune disorders. Thus, our findings provide a foundation
for the exploitation of novel IFN inhibitors, and we here
propose that a selective IKKα inhibitor designed to abro-
gate nuclear translocation of IRF7 and sequential type I
IFN production would be a promising tool for the treat-
ment of IFN-related diseases.
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